Panel discussion  - Redefining the speed of innovation

Information

  •  Industry actors and regulators managed to speed the development and approval time of the COVID-19 vaccine. Is it possible – and desirable – to maintain this momentum under more normal circumstances? Do we have the right priorities when it comes which pharma products are fast-tracked?     
  • Should the industry and regulators rethink how we approach clinical trials and what would that entail? What impact would new technologies play in that regard?   
  • What has the pandemic taught us about using Real World Data (RWD)? Does it hold the potential to revolutionize the way new drugs are tout on the market?  
  • How much does speed rely on stronger cooperation between researchers, public and industry actors? Can HERA find the right formula?   

Log in